<DOC>
	<DOCNO>NCT01157364</DOCNO>
	<brief_summary>This study evaluate safety efficacy new ophthalmic formulation bimatoprost patient open angle glaucoma ocular hypertension . At least 3 formulation evaluate base internal data review cohort . The study conduct 2 stage . Stage 1 open-label Stage 2 mask .</brief_summary>
	<brief_title>Safety Efficacy New Ophthalmic Formulation Bimatoprost Patients With Open Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis open angle glaucoma ocular hypertension Uncontrolled medical condition Anticipated wear contact lens study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>